HIF Hydroxylase Inhibitors for Kidney Function Improvement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively improve kidney function in subjects with impaired kidney function, leading to potential kidney failure, which affects millions of Americans and requires costly medical interventions like hemodialysis or transplantation.
Innovation Solution
Administering agents that inhibit hypoxia-inducible factor (HIF) hydroxylase activity, such as small molecule compounds like 2-oxoglutarate mimetics, to enhance kidney function by increasing glomerular filtration rate, reducing serum creatinine levels, and decreasing blood urea nitrogen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to treat impaired kidney function, then treatment is provided, but the methods fail to effectively improve kidney function leading to kidney failure
Solution Approach 1:
The patent changes the biochemical parameters within kidney cells by introducing expression vectors that encode specific proteins (such as HIF-1α, VEGF, EPO) to alter the cellular environment and promote kidney function improvement. This parameter change approach transforms the ineffective current treatment into a targeted molecular therapy that directly addresses the underlying cellular dysfunction.
Solution Approach 2:
The patent uses expression vectors and plasmids as intermediaries to deliver therapeutic genes into kidney cells. These vectors act as mediators that carry the genetic information for producing beneficial proteins (VEGF, EPO, HIF-1α) into the target cells, enabling the treatment to effectively improve kidney function where current direct methods fail.
2Reliability
If invasive medical procedures like hemodialysis or transplantation are used, then kidney failure is treated, but the need for serious medical procedures increases
Solution Approach 1:
The patent applies preliminary action by introducing expression vectors and therapeutic proteins into kidney cells before complete failure occurs. By delivering genes for VEGF, EPO, and HIF-1α production early in the disease process, the treatment prevents progression to kidney failure that would require complex interventions like hemodialysis or transplantation.
Solution Approach 2:
The patent enables kidney cells to self-service by introducing expression vectors that cause the cells themselves to produce therapeutic proteins (VEGF, EPO, HIF-1α). This self-production mechanism eliminates the need for continuous external administration of these proteins and avoids the complexity of invasive procedures, as the treated cells continuously generate the beneficial factors needed for kidney function maintenance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively improves kidney function by increasing glomerular filtration rate, lowering serum creatinine, and reducing blood urea nitrogen, potentially reducing the need for invasive medical procedures and improving quality of life.
Implementation Method 1
administering to the subject an effective amount of an agent that inhibits HIF hydroxylase activity
Data Source
AI summary
The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided.